Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (CH:UUD)
:UUD
UUD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Pharmaxis Ltd News
UUD FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Currently, no data Available
What is Pharmaxis Ltd’s market cap?
Currently, no data Available
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Feb 06, 2026 which is in 130 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Aug 28, 2025. The company reported -CHF0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.002.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Currently, no data Available
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of -CHF0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in CH:UUD
Pharmaxis Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.07 (― Downside)
AU$0.07 (― Downside)
Blogger Sentiment
Bullish
CH:UUD Sentiment 95%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.55%
12-Months-Change
Fundamentals
Return on Equity
-118.44%
Trailing 12-Months
Asset Growth
106.56%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.
UUD Stock 12 Month Forecast
Average Price Target
CHF0.07
Alterity Therapeutics
―
Genetic Signatures Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
PainChek Ltd
―
Options Prices
Currently, No data available
---